In March 2019, Chordia raised $27 million in a Series B financing round.

The company is a spin-out of Japanese pharma major Takeda, and had previously raised $11 million.

Chordia will use the money to advance its lead candidate, CTX-712, a selective pan-CDC-like kinase inhibitor, in a Phase I trial.